Skip to main content
Midas Edge

Harmony Biosciences Holdings, Inc.

For the period ended Jun 30, 2026. Filed Aug 4, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 4, 2026

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share and per share data)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ · Shares · ​ ​ · Amount · ​ ​ · capital · ​ ​ · (loss) income · ​ ​ · earnings · ​ ​ · equity
Balance as of March 31, 2026​57,867,389​$1​$717,370​$(413)​$193,391​$910,349
Net income—​—​—​​—​75,431​75,431
Unrealized loss on investments​—​​—​​—​​(314)​​—​​(314)
Restricted stock unit tax withholding, net of stock option exercises253,306​—​4,442​​—​—​4,442
Stock-based compensation—​—​9,335​​—​—​9,335
Balance as of June 30, 202658,120,695​$1​$731,147​$(727)​$268,822​$999,243
​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ · Shares · ​ ​ · Amount · ​ ​ · capital · ​ ​ · (loss) · ​ ​ · earnings · ​ ​ · equity
Balance as of December 31, 202557,726,170​$1​$708,968​$346​$160,903​$870,218
Net income—​—​—​​—​107,919​107,919
Unrealized (loss) on investments​—​​—​​—​​(1,073)​​—​​(1,073)
Restricted stock unit tax withholding, net of stock option exercises394,525​—​2,224​​—​—​2,224
Stock-based compensation—​—​19,955​​—​—​19,955
Balance as of June 30, 202658,120,695​$1​$731,147​$(727)​$268,822​$999,243
​​​​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ · Accumulated · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Accumulated · ​ · stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ · (loss) income · ​ ​ ​ · deficit · ​ ​ ​ · equity
Balance as of March 31, 202557,393,673​$1​$672,503​$245​$47,776​$720,525
Net income—​—​—​​—​39,776​39,776
Unrealized loss on investments​—​​—​​—​​(6)​​—​​(6)
Restricted stock unit tax withholding, net of stock option exercises144,196​—​1,329​​—​—​1,329
Stock-based compensation—​—​11,456​​—​—​11,456
Balance as of June 30, 202557,537,869​$1​$685,288​$239​$87,552​$773,080
​​​​​​​​​​​​​​​​​​
​ · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​ · ​ ​ ​ · ​ · ​ · ​ · Accumulated · ​ ​ ​ · ​ · ​ ​ ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · paid-in · ​ · comprehensive · ​ · Retained · ​ · stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · capital · ​ · income · ​ ​ ​ · earnings · ​ ​ ​ · equity
Balance as of December 31, 202457,144,887​$1​$656,872​$66​$2,216​$659,155
Net income—​—​—​​—​85,336​85,336
Unrealized gain on investments​—​​—​​—​​173​​—​​173
Restricted stock unit tax withholding, net of stock option exercises392,982​—​​4,462​​—​—​4,462
Stock-based compensation—​—​​23,954​​—​—​23,954
Balance as of June 30, 202557,537,869​$1​$685,288​$239​$87,552​$773,080

The* *accompanying notes are an integral part of the unaudited condensed consolidated financial statements

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.